Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Breast Neoplasms 3Vulvar Neoplasms 2Melanoma 2Liver Metastases 2Ulcer 1Skin Neoplasms 1Recurrence 1Rectal Neoplasms 1Pathologic Processes 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Liver Neoplasms 1Head and Neck Neoplasms 1Gynecological Cancers 1Desmoid Tumors 1Colorectal Neoplasms 1Breast Cancer Female 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × Electrochemotherapy × Clear all
NCT07404605 2026-02-19

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

Institute of Oncology Ljubljana

Phase NA Recruiting
150 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

European Institute of Oncology

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡